102 related articles for article (PubMed ID: 11562445)
1. Short-term inverse-agonist treatment induces reciprocal changes in delta-opioid agonist and inverse-agonist binding capacity.
Piñeyro G; Azzi M; De Léan A; Schiller P; Bouvier M
Mol Pharmacol; 2001 Oct; 60(4):816-27. PubMed ID: 11562445
[TBL] [Abstract][Full Text] [Related]
2. Reciprocal regulation of agonist and inverse agonist signaling efficacy upon short-term treatment of the human delta-opioid receptor with an inverse agonist.
Piñeyro G; Azzi M; deLéan A; Schiller PW; Bouvier M
Mol Pharmacol; 2005 Jan; 67(1):336-48. PubMed ID: 15496503
[TBL] [Abstract][Full Text] [Related]
3. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.
Liu JG; Prather PL
J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665
[TBL] [Abstract][Full Text] [Related]
4. Inverse agonistic effect of ICI-174,864 on the cloned delta-opioid receptor: role of G protein and adenylyl cyclase activation.
Chiu TT; Yung LY; Wong YH
Mol Pharmacol; 1996 Dec; 50(6):1651-7. PubMed ID: 8967989
[TBL] [Abstract][Full Text] [Related]
5. The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists.
Schiller PW; Weltrowska G; Berezowska I; Nguyen TM; Wilkes BC; Lemieux C; Chung NN
Biopolymers; 1999; 51(6):411-25. PubMed ID: 10797230
[TBL] [Abstract][Full Text] [Related]
6. Agonist Activity of the delta-antagonists TIPP and TIPP-psi in cellular models expressing endogenous or transfected delta-opioid receptors.
Martin NA; Terruso MT; Prather PL
J Pharmacol Exp Ther; 2001 Jul; 298(1):240-8. PubMed ID: 11408548
[TBL] [Abstract][Full Text] [Related]
7. Analysis of inverse agonism at the delta opioid receptor after expression in Rat 1 fibroblasts.
Mullaney I; Carr IC; Milligan G
Biochem J; 1996 Apr; 315 ( Pt 1)(Pt 1):227-34. PubMed ID: 8670111
[TBL] [Abstract][Full Text] [Related]
8. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.
Hirose N; Murakawa K; Takada K; Oi Y; Suzuki T; Nagase H; Cools AR; Koshikawa N
Neuroscience; 2005; 135(1):213-25. PubMed ID: 16111831
[TBL] [Abstract][Full Text] [Related]
9. Na+ modulation, inverse agonism, and anorectic potency of 4-phenylpiperidine opioid antagonists.
Emmerson PJ; McKinzie JH; Surface PL; Suter TM; Mitch CH; Statnick MA
Eur J Pharmacol; 2004 Jun; 494(2-3):121-30. PubMed ID: 15212965
[TBL] [Abstract][Full Text] [Related]
10. Inverse agonism and neutral antagonism at wild-type and constitutively active mutant delta opioid receptors.
Tryoen-Tóth P; Décaillot FM; Filliol D; Befort K; Lazarus LH; Schiller PW; Schmidhammer H; Kieffer BL
J Pharmacol Exp Ther; 2005 Apr; 313(1):410-21. PubMed ID: 15590769
[TBL] [Abstract][Full Text] [Related]
11. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of various proposed models of the receptor-bound conformation of H-Tyr-Tic-Phe-OH related delta-opioid antagonists.
Wilkes BC; Schiller PW
Biopolymers; 1995; 37(6):391-400. PubMed ID: 8589244
[TBL] [Abstract][Full Text] [Related]
13. (2S,3R) beta-methyl-2',6'-dimethyltyrosine-L-tetrahydroisoquinoline-3-carboxylic acid [(2S,3R)TMT-L-Tic-OH] is a potent, selective delta-opioid receptor antagonist in mouse brain.
Hosohata K; Varga EV; Alfaro-Lopez J; Tang X; Vanderah TW; Porreca F; Hruby VJ; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 2003 Feb; 304(2):683-8. PubMed ID: 12538822
[TBL] [Abstract][Full Text] [Related]
14. Characterization of specific opioid binding sites in neural membranes from the myenteric plexus of porcine small intestine.
Townsend D; Portoghese PS; Brown DR
J Pharmacol Exp Ther; 2004 Jan; 308(1):385-93. PubMed ID: 14569065
[TBL] [Abstract][Full Text] [Related]
15. Co-expression of mu and delta opioid receptors as receptor-G protein fusions enhances both mu and delta signalling via distinct mechanisms.
Snook LA; Milligan G; Kieffer BL; Massotte D
J Neurochem; 2008 May; 105(3):865-73. PubMed ID: 18182056
[TBL] [Abstract][Full Text] [Related]
16. Short- and long-term regulation of adenylyl cyclase activity by delta-opioid receptor are mediated by Galphai2 in neuroblastoma N2A cells.
Zhang L; Tetrault J; Wang W; Loh HH; Law PY
Mol Pharmacol; 2006 Jun; 69(6):1810-9. PubMed ID: 16525132
[TBL] [Abstract][Full Text] [Related]
17. Characterization of opioid-binding sites in zebrafish brain.
González-Núñez V; Barrallo A; Traynor JR; Rodríguez RE
J Pharmacol Exp Ther; 2006 Feb; 316(2):900-4. PubMed ID: 16207834
[TBL] [Abstract][Full Text] [Related]
18. Agonist-, antagonist-, and inverse agonist-regulated trafficking of the delta-opioid receptor correlates with, but does not require, G protein activation.
Zaki PA; Keith DE; Thomas JB; Carroll FI; Evans CJ
J Pharmacol Exp Ther; 2001 Sep; 298(3):1015-20. PubMed ID: 11504798
[TBL] [Abstract][Full Text] [Related]
19. Internalization and Src activity regulate the time course of ERK activation by delta opioid receptor ligands.
Audet N; Paquin-Gobeil M; Landry-Paquet O; Schiller PW; Piñeyro G
J Biol Chem; 2005 Mar; 280(9):7808-16. PubMed ID: 15632168
[TBL] [Abstract][Full Text] [Related]
20. Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonists.
Neilan CL; Akil H; Woods JH; Traynor JR
Br J Pharmacol; 1999 Oct; 128(3):556-62. PubMed ID: 10516632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
